

V.Yu. Barshteyn
THE HISTORY OF PHYTOTHERAPY IN MONUMENTS OF MATERIAL CULTURE. ANTIQUITY AND EARLY MIDDLE AGES

Key words: history of phytotherapy, art medal
 The story about outstanding personages in history of phytotherapy in antiquity and early middle ages is illustrated by monuments of material culture - art medals by the sculptors of France, USA, Portugal, Ukraine and Russia.

616.36-002-003.82.6-036.82

- 1
- 2
- 2
- 3
- 1
- 4
- 1
- 2
- 3
- 4

... () [8, 21].

() [3, 27, 29]. [27].

... () [11], [27]. [16],

« » () [6, 7, 15].

() [9]. 300-500 5000 D, 70-75% " () [7, 15, 19, 26, 30].

11-12 [9]. [9, 10]. () [27]. [17]. [10]. [1, 25]. [4, 8, 21]. [3, 29], [27], ()

[8]. [27]. (,)

[12, 13] [17, 25]. 1-2 ; 2 3

» «) 3-4 0,25 (1

» () « 2-3 1 2

» (UA/2117/02/01) (18 22.01.07) [12].

0109U007770) « ((Holarrhena antidysenterica), (Myrtus communis L.), (Berberis aristata), (Aegle marmelos) (Quercus infectoria Oliv.), (Butea monospurma) [12, 13].

0108U009463). » ((Holarrhena antidysenterica) B, C, D, E F;

[30]. 75 28 55 37 (49,3%)

38 (50,7%) -

[31]. [31, 33]. (Myrtus communis L.) 1,8-2,2%

13.06.2005 271 [15].

[32]. [31, 33]. (Berberis aristata) 7,7% , 3,5-6%

() [15].

[30]. Berberis aristata 1

(E. coli Candida). [32].

[15].

(); Vibrio cholerae, Staph. aureus, Escherichia coli, Salmonella, Schigella . [32].

Candida - [31, 33],

(43) (32). [15].

() (Aegle marmelos) [33].

() [31].

1% [32]. [22].

() [5] () [2]

[31, 33]. ().

(Fagaceae), Athlon 3600+ AMD

[15]. Windows professionalxp, Microsoft Office 2003, Stadia 6.1/ prof Statistic [20].

[30], [20].

[14, 15]. (monosp rma) - [30].

(7,3',4'-) [31].

[33]. ()

[13].

[18]. () [10].

(/2885/01/02) 573 18.08.06

[17]. ()

7000 2-3 4-6 ()

[1]. [14].

G, ;

[1, 14, 17].

[25]. () (<0,05) 8,2 /

[23]. 10,5 / , 2,2 2,4 (<0,05) 6,4 . 6,8 .;

1,8-2,1 (<0,05) (<0,05) (<0,05)

[28]. [25]. (Bifidobacterium spp.), (Lactobacterium spp.) E. coli

[24]. 105-6 (Staph.

aureus Staph. saprophyticus); (Proteus mirabilis
. vulgaris), Candida.
- (- (0,52±0,02) / ; <0,001) 4,2
(. 1). (2,2±0,12) /

				2
		(n=43)	(n=32)	
,	0,52±0,02	2,2±0,12 1<0,001	1,97±0,14 1<0,001	<0,05
,	3,2±0,2	8,3±0,3 1<0,001	8,1±0,2 1<0,001	<0,05
,	9,2±0,18	18,8±0,28 1<0,001	18,5±0,32 1<0,001	<0,05
, %	3,5±0,15	9,4±0,6 1<0,001	9,0±0,8 1<0,001	<0,05

: .1 2 I ; 2-

(1,97±0,14) / . 3,8 (<0,001) - (18,5±0,32)
- 2 (9,2±0,18) ; <0,001) 2,04
(<0,001).
- (9,3±0,6)% ,
- 2,67 (3,1±0,02%; <0,001),
- (9,0±0,8)% ,
- 2,66 (<0,001).
(8,3±0,3) / , 2,56
(3,2±0,2 / ; <0,01);
2,5
(8,1±0,2) / (<0,01).
- 4,2
(18,8±0,28) / - (0,53±0,05) ,
- (>0,05) (. 2).

				2
		(n=43)	(n=32)	
,	0,52±0,02	0,53±0,05 1<0,05	1,22±0,08 1<0,01	<0,01
,	3,2±0,2	3,5±0,15 1<0,05	5,5±0,2 1<0,01	<0,05
,	9,2±0,18	9,6±0,16 1<0,05	13,8±0,18 1<0,01	<0,05
, %	3,5±0,15	3,6±0,12 1<0,05	5,8±0,15 1<0,05	<0,05

(1,22±0,08) / , 2,3
(<0,01), 2,34
- (<0,01).

2,4 (3,5±0,15) (<0,05).
 / , (5,5±0,2)
 / , 1,5 (,) ,
 (<0,05). 1,7 , 33,3%
 (9,6±0,16) / , (<0,05).
 (13,8±0,18) / ,
 1,47 1,5 (<0,05)
 1,4 : 1. (), ()
 (3,6±0,3%).
 2,6 (<0,01).
 1,4 (<0,05), 1,9 ,
 1,37 (<0,05). ((3-4) ,)
 ()
 () ,
 2. ,
 8,2 (' /) 10,5 / ,
 2,2 2,4
 - 1,8-2,1 ,
 (<0,05)
 6,4 . 6,8 ;
 108-109, 108-109,
 E.coli (<0,05) (<0,05) (<0,05)
 <104,)
 3. , ,
 Candida 103-104 <104. ,
 4 (<0,001),
 E.coli » , 2,53
 104-5 , (2,0 ; 3,0
 ,) ,
 Candida (« » .
) ,
 4. ,
 5. .

1. // ... // 2007. - 17 (174).
 2. // ... // -1988.
 3. // ... // - 2003. - 10. - 31-39.
 4. // ... // - 2002. - 4. - 21 - 25.
 5. // ... // - 1988. - 2. - 60-63.
 6. // ... // : 14.01.02. - 2004. - 33.
 7. // ... // - 2002. - 70-72.
 8. // ... // - 2005. - 5 (25). - 80 - 83.
 9. // ... // - 1997. - 1. - II-16.
 10. // ... // - 2006. - I (35). - 3 -13.
 11. // ... // , 2007. - 256.
 12. // ... // 22.01.2007.
 13. // ... // - 2010. - 3. - 3-9.
 14. // ... // , 1994. - 232.
 15. // ... // , 1990. - 544.
 16. // ... // , 2008. - 134-135.

17. H. // 18.08.2006., 73.
 18. // ... // - 2009. - 7, 2. - 108-113.
 19. // ... // H. // - 2002. - 3-4. - 3-11.
 20. // ... // , 2000. - 160.
 21. // ... // 2003. - 3. - 7- 13.
 22. // ... // [] // HU - 10. - 13-18.
 23. // ... // in vitro / - 2010. - 44-48.
 24. // ... // , 1990. - 64.
 25. // ... // H. // - 2009. - 2-3. - 138-141
 26. H£. // - 2007. - 6. - /H£. 79 - 8.
 27. H£. // H. // : , 2000. - 448.
 28. // ... // - 2011. - 14, 1. - 29. Brunt E.M. *Non-alcoholic steatohepatitis definition and pathology* /E.M. Brunt//Sem. Liv. Dis. - 2001. - Vol. 21. - P. 3 -16.
 30. Graiger N. *Herbal drugs and phytopharmaceuticals: a handbook for practice and Scientific Basis* / N.Graiger. - London, 2001. - 780 p.
 31. Khare C.P. *Indian medicinal plants* / C.P. Khare. - Berlin: Springer Verlag, 2007. - 836p.
 32. Pengelly A. *The constituents of medicinal plants. An introduction to the chemistry and therapeutics of herbal medicines* / A. Pengelly. - New York: Sunflower herballis, 2006. - 10 p.
 33. *The aurvedic pharmacopoea of India.* - Government of India Ministry of health and family welfare department of aush. - Dely: ed. Government of India. Ministry of health and family welfare, 2007. - 862 p.

I O ACO
AKIMBHOTO
HEA KO Q H
KOM A
ME A Q I HO
H K E HA X O X HA
, C O EH
C IO OM K E H KA

" ()
() , ()

T.P.Garnik, V.M. Frolov, O.V. ^glova, . Peresadin,
V.O. Petrisheva, . M schich
**EFFECTIVITY OF COMBINATION OF MODERN
PHYTYOPREPARATION ENTOBAN AND METABOLIC
ACTIVITY PREPARATION NUCLEINAS AT THE PATIENTS
WITH NON-ALCOHOLIC STEATOHEPATITIS COMBINED
WITH INTESTINE DISBIOSIS**

Key words: non-alcoholic steatohepatitis, intestine disbiosis,
entoban, nucleinas, treatment

The influence of combination of phytopreparation entoban and metabolic activity preparation nucleinas in clinical picture, lipoperoxidation activity and level of average molecules (AM) in the blood serum at the patients with non-alcoholic steatohepatitis (NASH) combined with intestine disbiosis (ID) was detected. It was set that application of this combination of preparations provided of the proof clinical-biochemical remission, normalization of lipoperoxidation indices and AM level in the serum. These data declaimed about using of combination of phytopreparation entoban and metabolic activity preparation nucleinas in treatment complex of the patients with NASH combined with ID.

XHK 616.36-002.35.14:578.16.32

2
^

OXO EHH HA OKIHOB
CTOBI XBO X H A X OHI H OKC H , C O EH
X OHI H M HEKA K O H M XO E C OM HA I

[1].

[8, 15].

(),
[2, 10, 36].

[21].

[8, 13].

[2, 22].